Abstract P228 – Table 1. Participants included for each virological outcome and multivariate analysis of factors associated with viral blip, low‐level viraemia, virological failure and virological suppression. Models were adjusted for gender, age, year of ART initiation, HIV transmission route, ethnicity, HBV and HCV status, body mass index, smoking status, origin region, prior AIDS diagnosis, baseline HIV‐1 RNA, baseline CD4+ T‐cell count and initial ART classes.
Virological outcome	Viral blip	Low‐level viraemia	Virological failure	Virological suppression week 48	Virological suppression week 96
N included	2977	2977	3116	3055	2435
N with endpoint	448	113	162	2767	2262
% (95% CI)	N/A	N/A	N/A	90.6 (89.5 to 91.6)	92.9 (91.9 to 93.9)
K‐M % at 12 months (95% CI)	10.9 (7.9 to 13.9)	3.2 (1.5 to 4.9)	4.7 (2.7 to 6.7)	N/A	N/A
Multivariate analysis	Adjusted HR (95% CI), p‐value	Adjusted HR (95% CI) p‐value	Adjusted HR (95% CI) p‐value	Adjusted OR (95% CI) p‐value	Adjusted OR (95% CI) p‐value
HIV viral load, HIV‐1 RNA copies/mL
10 000 or under	0.52 (0.36 to 0.75), <0.001	0.45 (0.17 to 1.18), 0.10	0.70 (0.44 to 1.11), 0.13	1.41 (0.91 to 2.20), 0.13	1.18 (0.69 to 2.00), 0.55
10 001 to 100 000	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)
>100 000	1.94 (1.55 to 2.42), <0.001	2.54 (1.58 to 4.07), <0.001	0.90 (0.61 to 1.32), 0.58	0.51 (0.37 to 0.70), <0.001	0.57 (0.38 to 0.84), 0.004
CD4+ T‐cell count, cells/μL
200 or under	2.84 (2.07 to 3.89), <0.001	7.87 (3.40 to 18.20), <0.001	2.94 (1.78 to 4.87), <0.001	0.42 (0.28 to 0.62), <0.001	0.40 (0.24 to 0.66), <0.001
201 to 350	2.07 (1.51 to 2.82), <0.001	5.13 (2.19 to 11.98), <0.001	1.02 (0.58 to 1.79), 0.95	0.63 (0.41 to 0.95), 0.03	0.57 (0.34 to 0.93), 0.02
351 to 500	1.33 (0.96 to 1.85), 0.09	3.13 (1.29 to 7.60), 0.01	1.34 (0.82 to 2.20), 0.25	0.93 (0.60 to 1.44), 0.75	1.35 (0.76 to 2.39), 0.31
>500	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)	1.0 (Ref)

K‐M, Kaplan‐Meier; N, number of participants; N/A, not applicable.